

## PRETERM BABIES SUFFER AND HAVE A HIGH RISK OF DEATH



Bronchopulmonary Dysplasia (BPD) is a chronic lung disease causing the majority of prolonged and repeated hospitalizations and deaths of preterm babies

1

## FACTS ABOUT BPD

- Very low birth weight (VLBW) <1,000g (2.2lb) => require mechanical ventilation, oxygen support
  - ⇒49% die
  - ⇒61% die or have profound impairment
  - ⇒73% die or have impairment
- Increased need for re-hospitalizations
- Most common and most extensively studied complication of prematurity
- Incidence of 10% of VLBW infants and 40% of extremely VLBW infants
- An estimated 40,000 infants annually are at risk for BPD
- Costs to treat infants with BPD is \$2.4B annually (hospitalization stay of ~120 days)
- In 2009 global annual Surfactant sales \$240MM (US: \$75MM)
- Orphan indication

2

## WHAT IS BPD ?

- Pathogenesis
  - Tissue damage as a result of oxygen therapy and mechanical ventilation
  - Inflammation and infection of the lung
  - Requirement for oxygen therapy at 28 days of age or 36 weeks post-menstrual age
- Symptoms
  - ⇒ Breathing difficulties
  - ⇒ Problems with feeding and swallowing
  - ⇒ Pulmonary hypertension (increased pressure in the pulmonary arteries with high blood pressure)
  - ⇒ Cor pulmonale (failure of the right side of the heart)


3

## AT-100 FOR PREVENTION AND TREATMENT OF BPD

- AT-100 is a novel targeted therapy in development for prevention and treatment of Bronchopulmonary Dysplasia (BPD) in babies with a low birth weight
- Pivotal animal model data provide significant evidence that AT-100 will improve symptoms and survival in preterm born babies
- Broad patent protection
- Manufacturing pathway established
- Strong collaboration with [Cincinnati Children's Hospital Medical Center](#)

4


## FUNCTIONS OF AT-100



5



## ROLE OF AT-100 IN PREVENTION OF BPD



6

## THE MARKET

- FDA and other Regulatory Agencies are waiting for a solution of BPD
- Health Care Insurance providers anxious to reduce costs for the management of VLBW babies
- Annual sales for treatment of BPD in the USA: \$200-300MM
- Other target markets such as COPD, Cystic Fibrosis, Asthma and Influenza A cover multi-billion dollar market

⇒ **AT-100 has blockbuster potential, i.e. annual peak year sales of > \$1B**

7

## COMPETITION

Product	Development stage	Prevents, treats BPD	Anti-inflammatory	Safe and well tolerated	Prolongs survival of VLBW babies
Oral steroids	Market	No	Yes	No	No
Systemic steroids	Market	Yes	Yes	No	Yes
Vitamin A	Market	No	No	Yes	No
Oxygen	Market	No	No	No	No
Surfactant (SP-B, SP-C)	Market	No	No	Yes	Yes
CPAP	Market	??	No	(Yes)	?
AT-100	preclinical	Yes	Yes	Yes	Most likely

8

## INVESTMENT PROPOSAL

- Investment: \$ 4MM
- Post money valuation: \$10MM
- Closing date: 31 March 2014
- Use of proceeds:
  - Production of AT-100 in larger quantities and for use in humans
  - Animal studies for toxicology and life cycle management
  - Planning of clinical Ph I/II study


9

## CONTACT INFORMATION

Marc Salzberg, M.D.  
 President & CEO  
 Phone: 470-375-3915  
 Mobile: 513-212-7547  
 Email: [salzberg@airwaytherapeutics.com](mailto:salzberg@airwaytherapeutics.com)

10

**Marc O. Salzberg, MD**  
*President & CEO*



**Jan S. Rosenbaum, Ph.D.**  
*Chief Scientific Officer*